The Elimination of Hepatitis C as a Public Health Threat

被引:7
作者
Hellard, Margaret [1 ,2 ,3 ,4 ,5 ]
Schroeder, Sophia E. [1 ,2 ]
Pedrana, Alisa [1 ,2 ]
Doyle, Joseph [1 ,3 ]
Aitken, Campbell [1 ,2 ]
机构
[1] Burnet Inst, Dis Eliminat Program, Melbourne, Vic 3004, Australia
[2] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia
[3] Monash Univ, Alfred Hosp, Dept Infect Dis, Melbourne, Vic 3004, Australia
[4] Univ Melbourne, Doherty Inst, Melbourne, Vic 3000, Australia
[5] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic 3000, Australia
来源
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE | 2020年 / 10卷 / 04期
关键词
INFECTION DISEASE BURDEN; DIRECT-ACTING ANTIVIRALS; VIRUS-INFECTION; HISTORICAL EPIDEMIOLOGY; VIRAL-HEPATITIS; HCV TREATMENT; INJECT DRUGS; COST-EFFECTIVENESS; SELECT COUNTRIES; SUBSTITUTION THERAPY;
D O I
10.1101/cshperspect.a036939
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hepatitis C virus is a global public health threat, affecting 71 million people worldwide. Increasing recognition of the impact of this epidemic and recent advances in biomedical and technical approaches to hepatitis C prevention and cure have provided impetus for the World Health Organization (WHO) to call for global elimination of hepatitis C as a public health threat by 2030. This work reviews the feasibility of hepatitis C elimination and pathways to overcome existing and potential future barriers to elimination. Drawing on costeffectiveness modeling and providing examples of successful implementation efforts across the globe, we highlight the resources and strategies needed to achieve hepatitis Celimination. A timely, multipronged response is required if the 2030 WHO elimination targets are to be achieved. Importantly, achieving hepatitis Celimination will also benefit the communitywell beyond 2030.
引用
收藏
页数:18
相关论文
共 112 条
  • [1] The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs
    Aitken, C. K.
    Agius, P. A.
    Higgs, P. G.
    Stoove, M. A.
    Bowden, D. S.
    Dietze, P. M.
    [J]. EPIDEMIOLOGY AND INFECTION, 2017, 145 (04) : 796 - 801
  • [2] Alcorn T, 2018, ATLANTIC
  • [3] Strategies to manage hepatitis C virus infection disease burden - volume 3
    Alfaleh, F. Z.
    Nugrahini, N.
    Maticic, M.
    Tolmane, I.
    Alzaabi, M.
    Hajarizadeh, B.
    Valantinas, J.
    Kim, D. Y.
    Hunyady, B.
    Abaalkhail, F.
    Abbas, Z.
    Abdou, A.
    Abourached, A.
    Al Braiki, F.
    Al Hosani, F.
    Al Jaberi, K.
    Al Khatry, M.
    Al Mulla, M. A.
    Al Quraishi, H.
    Al Rifai, A.
    Al Serkal, Y.
    Alam, A.
    Alashgar, H. I.
    Alavian, S. M.
    Alawadhi, S.
    Al-Dabal, L.
    Aldins, P.
    Alghamdi, A. S.
    Al-Hakeem, R.
    Aljumah, A. A.
    Almessabi, A.
    Alqutub, A. N.
    Alswat, K. A.
    Altraif, I.
    Andrea, N.
    Assiri, A. M.
    Babatin, M. A.
    Baqir, A.
    Barakat, M. T.
    Bergmann, O. M.
    Bizri, A. R.
    Chaudhry, A.
    Choi, M. S.
    Diab, T.
    Djauzi, S.
    El Hassan, E. S.
    El Khoury, S.
    Estes, C.
    Fakhry, S.
    Farooqi, J. I.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 42 - 65
  • [4] Disparity in market prices for hepatitis C virus direct-acting drugs
    Andrieux-Meyer, Isabelle
    Cohn, Jennifer
    Affonso de Araujo, Evaldo S.
    Hamid, Saeed S.
    [J]. LANCET GLOBAL HEALTH, 2015, 3 (11): : E676 - E677
  • [5] [Anonymous], 2018, JUST 12 COUNTRIES WO
  • [6] [Anonymous], 2016, COMB HEP B C REACH E
  • [7] [Anonymous], 2017, ESSENTIAL PRINCIPLES
  • [8] [Anonymous], INN FIN HEP B C PREV
  • [9] [Anonymous], WORLD INN SUMM HLTH
  • [10] [Anonymous], 2017, Enhancing urban resilience in the Greater Accra Metropolitan Area No. 115296, P1